Skip to nav Skip to content

The treatment paradigm of HER2-positive breast cancer has grown significantly for early-stage and metastatic settings. 

"In the metastatic setting, where there were significant unmet needs, tucatinib (Tukysa) and fam-trastuzumab deruxtecan-nxki (Enhertu) represent welcome additions to the armamentarium,” said Christine Sam, MD, assistant member, Senior Adult Oncology Program, Moffitt Cancer Center.

For more information or to read the full article from OncLive®, click here.